ORMP - Oramed Pharmaceuticals Inc.
| Previous Close | 3.9500 |
| Open | 3.9600 |
| Bid | 4.0200 x 1000 |
| Ask | 4.0900 x 900 |
| Day's Range | 3.9200 - 4.1500 |
| 52 Week Range | 2.3200 - 6.0500 |
| Volume | 326,166 |
| Avg. Volume | 240,345 |
| Market Cap | 72.576M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7210 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
- PR Newswire
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $4.00 per share. All of the shares in the offering are to be sold by Oramed. Oramed has granted the underwriters a 45-day option to purchase up to 787,500 additional shares of common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about March 2, 2020, subject to the satisfaction of customary closing conditions.
- Benzinga
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...
- PR Newswire
Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the underwritten public offering are to be sold by Oramed. Oramed intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discount.
- PR Newswire
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
Primary endpoints successfully met
- Simply Wall St.
Have Insiders Been Buying Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- PR Newswire
Oramed to Present at BIO CEO & Investor Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the BIO CEO & Investor Conference in New York City.
- PR Newswire
Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientific Advisory Board.
- PR Newswire
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent to grant the Company a patent for its invention titled "Methods and Compositions for Oral Administration of Proteins," addressing oral compositions comprising protease inhibitors, which are a key component of the platform technology that protects therapeutic proteins in the digestive system.
- PR Newswire
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.
- PR Newswire
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.
- PR Newswire
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a video message from Mr. Kidron click here.
- Simply Wall St.
Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?
Nadav Kidron became the CEO of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in 2006. First, this article will compare CEO...
- Zacks Small Cap Research
ORMP: Multiple Data Readouts on the Horizon…
By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Financial Update On November 27, 2019, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) filed form 10-K with financial results for the fiscal year 2019 ending August 31, 2019. The company reported revenues of $2.7 million for the fiscal year 2019 compared to $2.4 million for 2018. The revenues are related to the license agreement
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Oramed Pharmaceuticals Inc. (ORMP)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]
- PR Newswire
Oramed Appoints Dr. Arie Mayer to Board of Directors
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Arie Mayer, Ph.D. to its Board of Directors.
- Simply Wall St.
Introducing Oramed Pharmaceuticals (NASDAQ:ORMP), The Stock That Dropped 41% In The Last Three Years
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shareholders will doubtless be very grateful to see the share price up 32...
- PR Newswire
Oramed to Present a Scientific Poster at International Diabetes Federation Congress
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it will present a scientific poster at the 2019 International Diabetes Federation (IDF) Congress in Busan, South Korea to be held December 2-6. Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.
- PR Newswire
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology
NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same" has been granted by the Japanese Patent Office. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
- PR Newswire
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes. Panelists presenting the data included: Dr. Joel Neutel, Principal Investigator of the study and Director of Research at Orange County Research Center; Kenneth Homer, the trial's biostatistician; Dr. Ramachandra Naik, Professor of Medicine/Endocrinology at SUNY Upstate Medical University; and Dr. Alexander Fleming, CEO of Kinexum, and former Head of Clinical Review of Endocrine and Metabolic Drugs at the U.S. Food and Drug Administration (FDA).
- PR Newswire
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.
- PR Newswire
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.
- Simply Wall St.
How Does Investing In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Impact The Volatility Of Your Portfolio?
Anyone researching Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) might want to consider the historical volatility of the...
- Simply Wall St.
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- PR Newswire
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP.TA) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will present and participate in one-on-one meetings at the 2019 Ladenburg Thalmann Healthcare Conference to be held on September 24, 2019 in New York, NY.
- Yahoo Finance Video
Oramed working on first insulin pill for diabetes
Oramed Pharmaceuticals is waiting on approval from the FDA after its new insulin pill to treat type two diabetes had successful results in its phase two trial. Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss on The First Trade.
